Last reviewed 2026-05-21 · How we verify

R-2487 DP

Rise Therapeutics LLC · Phase 1 active Small molecule ✓ Verified May 2026 Quality 3/100

R-2487 DP is a Small molecule drug developed by Rise Therapeutics LLC. It is currently in Phase 1 development. Also known as: Drug.

R-2487 DP is a small molecule intervention being studied for its potential effects on various conditions, including arthritis and Sjögren's Syndrome. A clinical trial (NCT05961592) is investigating the safety, drug exposure, and clinical activity of R-2487 DP in patients with rheumatoid arthritis.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	R-2487 DP
Also known as	Drug
Sponsor	Rise Therapeutics LLC
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

R-2487 in Patients With Rheumatoid Arthritis (PHASE1)
R-2487 in Patients With Sjogren's Syndrome (SS) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

R-2487 DP CI brief — competitive landscape report
R-2487 DP updates RSS · CI watch RSS
Rise Therapeutics LLC portfolio CI

Frequently asked questions about R-2487 DP

What is R-2487 DP?

R-2487 DP is a Small molecule drug developed by Rise Therapeutics LLC.

Who makes R-2487 DP?

R-2487 DP is developed by Rise Therapeutics LLC (see full Rise Therapeutics LLC pipeline at /company/rise-therapeutics-llc).

Is R-2487 DP also known as anything else?

R-2487 DP is also known as Drug.

What development phase is R-2487 DP in?

R-2487 DP is in Phase 1.

Manufacturer: Rise Therapeutics LLC — full pipeline
Also known as: Drug

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing